What question did this study set out to answer?

The central aim is to explore the therapeutic potential of the small molecule inhibitor AOH1996 in combination with histone deacetylase inhibitors for treating cancers.

April 5, 2026Cancer Research

Therapeutic Potential of PCNA and HDAC Inhibitor Combinations in Cancers

View Full Paper

Ask AI

Bookmark

The central aim is to explore the therapeutic potential of the small molecule inhibitor AOH1996 in combination with histone deacetylase inhibitors for treating cancers.
Combination treatment of AOH1996 with HDAC inhibitors belinostat and vorinostat
Cell growth inhibition assays on neuroblastoma, breast, colon, and CTCL cell lines
CRISPR interference screens to identify involved HDACs (HDAC3 and HDAC6)
Mechanistic studies analyzing DNA damage response, cell cycle arrest, and apoptosis
AOH1996 combined with HDAC inhibitors showed synergistic growth inhibition in various cancer cell lines
Enhanced DNA damage response and cell cycle arrest observed in CTCL cells treated with AOH1996 and HDAC inhibitors
AOH1996 and vorinostat demonstrated synergistic inhibition in CTCL-derived cell lines.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Demonstrates synergistic growth inhibition in cutaneous T-cell lymphoma using PCNA and HDAC inhibitor combinations, suggesting a new treatment pathway.

Cite This Study

Li et al. (2026) studied this question.

synapsesocial.com/papers/69d1fdd4a79560c99a0a42ab https://doi.org/10.1158/1538-7445.am2026-7057

View Full Paper

Ask AI

Bookmark

Implication

Demonstrates synergistic growth inhibition in cutaneous T-cell lymphoma using PCNA and HDAC inhibitor combinations, suggesting a new treatment pathway.

Therapeutic Potential of PCNA and HDAC Inhibitor Combinations in Cancers

Key Points

Discussion

Implication

Cite This Study

Therapeutic Potential of PCNA and HDAC Inhibitor Combinations in Cancers

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider